ADAMTSL2 and metabolic dysfunction-associated steatotic liver disease: A retrospective study reported on two novel biomarkers for the detection of significant fibrosis among NAFLD patients, ADAMTSL2, and a combination of 8 sensitive proteins—NFPP [30].